Bio-Rad Laboratories (BIO) EBT (2009 - 2026)

Bio-Rad Laboratories (BIO) has 18 years of EBT data on file, last reported at -$689.8 million in Q1 2026.

• On a quarterly basis, EBT fell 927.1% year-over-year to -$689.8 million in Q1 2026; TTM through Mar 2026 was $222.3 million, a 108.08% increase from a year earlier, with the FY2025 full-year figure at $995.5 million, up 142.5% from the prior year.
• EBT for Q1 2026 stood at -$689.8 million, down from $929.2 million in the prior quarter.
• Over the last five years, EBT for BIO reached as high as $1.1 billion in Q4 2022 and fell as low as -$4.4 billion in Q1 2022.
• Historically, EBT has averaged -$446.5 million across 5 years, with a median of $83.4 million in 2025.
• Across the five-year window, EBT soared 528.44% in 2024 and tumbled 927.1% in 2026, its largest moves.
• Year by year, EBT stood at $1.1 billion in 2022, then slumped by 60.75% to $428.4 million in 2023, then plunged by 312.16% to -$908.9 million in 2024, then surged by 202.23% to $929.2 million in 2025, then slumped by 174.24% to -$689.8 million in 2026.
• Per Business Quant data, the three most recent EBT figures were -$689.8 million in Q1 2026, $929.2 million in Q4 2025, and -$431.1 million in Q3 2025.